Cycle on Aug 19, 2026

I will list the open threads and watches for this topic to see what needs to be tracked or updated.

I will search the web for recent major medical, scientific, and public health developments, including clinical trial readouts, FDA decisions, space launches, or disease outbreaks over the last week.

This is fascinating. Let's look at some key highlights from the search results: 1. **Merck and Moderna's mRNA cancer vaccine (INT, V940/mRNA-4157)**: "In a first, an mRNA cancer vaccine succeeds in late-stage clinical trial" (Melanoma Phase 3 success announced on Wednesday, Aug 19, 2026). Let's search for this. 2. **Ultragenyx's gene therapy for GSDIa (Glycogen Storage Disease Type Ia)**: "Ultragenyx receives FDA approval for gene therapy treating GSDIa" (based on Phase 3 GlucoGene study). Let's search for this. 3. **Regeneron's FDA approval for "Pasatru" (anti-activin A drug)** for fibrodysplasia ossificans progressiva (FOP). This is an ultra-rare disorder. Let's search for this. 4. **Measles Outbreak**: "Kindergarten measles vaccination exemptions climb as outbreak confirmed in southern Iowa", "Pennsylvania deals with its worst measles outbreak in 20 years", "CDC data shows childhood vaccinations down". This relates to our watch on US measles elimination status! Let's check this further. Let's do a search on the Merck/Moderna mRNA cancer vaccine Phase 3 trial results. This is highly consequential.

This is a monumental result. The Merck/Moderna mRNA cancer vaccine (intismeran autogene, V940/mRNA-4157) met its primary endpoint of recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in the Phase 3 INTerpath-001 trial for patients with completely resected Stage IIB-IV melanoma. Let's also look into the Ultragenyx FDA approval for GSDIa gene therapy. Let's do a search on this.

Excellent! Let's fetch the actual press releases or articles to confirm the details. Let's fetch: - `https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/` - `https://www.statnews.com/2026/08/19/mrna-cancer-vaccine-trial-melanoma-merck-moderna/` - `https://www.stocktitan.net/news/RARE/ultragenyx-announces-u-s-fda-approval-of-genglycostm-gene-therapy-7d8gtl2n9apb.html` Let's do this.

This is excellent. Let's look at the details: - **Trial name**: Phase 3 INTerpath-001 (NCT05933577) - **Therapy**: intismeran autogene (V940 or mRNA-4157) in combination with Keytruda (pembrolizumab) vs Keytruda alone. - **Population**: Completely resected stage IIB-IV melanoma (1,137 patients, randomized 2:1). - **Outcome**: Met primary endpoint of recurrence-free survival (RFS) and key secondary endpoint of distant metastasis-free survival (DMFS). - **Significance**: "This represents the first positive Phase 3 readout for an individualized neoantigen therapy (INT) and for an mRNA-based cancer therapy, as well as the first Phase 3 study to demonstrate a clinically meaningful improvement over KEYTRUDA alone, a standard-of-care immunotherapy, in the adjuvant setting for patients with resected melanoma." - **Next steps**: Present data at an upcoming international medical meeting and engage with regulators. Let's fetch the Ultragenyx press release as well to get exact details on GENGLYCOS. Let's fetch `https://www.stocktitan.net/news/RARE/ultragenyx-announces-u-s-fda-approval-of-genglycostm-gene-therapy-7d8gtl2n9apb.html`.

This is a very important FDA approval. Let's look at the details: - **Drug name**: GENGLYCOS (pariglasgene brecaparvovec-opnr), also known as DTX401. - **Indication**: Adult and pediatric patients 8 years and older with glycogen storage disease type Ia (GSDIa). - **Mechanism**: First approved gene therapy designed to treat the underlying cause of GSDIa. It reduces daily cornstarch intake as an adjunct to nutritional management. - **Basis of approval**: 48-week randomized, double-blind, placebo-controlled Phase 3 GlucoGene study in 46 participants, in which DTX401 significantly reduced cornstarch requirements vs placebo (p<0.001). - **Post-marketing requirements**: 2-year safety and efficacy data from open-label commercial treatment of 50 patients and 20 controls, and long-term follow-up via the GSDIa Disease Monitoring Program for up to 10 years. - **Contraindications/Safety**: Contraindicated in patients with severe hepatic fibrosis or cirrhosis. Immune-mediated hepatotoxicity (ALT/AST elevations in 71% of treated patients). Adrenal insufficiency (24%), hypertriglyceridemia (29%), nausea (38%), anaphylaxis (10%). - **Manufacturing**: Manufactured at Ultragenyx's Bedford, MA facility. - **Priority Review Voucher**: Ultragenyx received an FDA Priority Review Voucher upon approval. Now let's check the other findings that have come up: 1. **Regeneron's "Pasatru" (anti-activin A drug)** for fibrodysplasia ossificans progressiva (FOP). Let's search for this to find the exact approval date and details. 2. **Measles outbreak and vaccination drop-off in the US**: KCRG/Iowa, Pennsylvania, etc. This is relevant to our watch on whether the US will lose its measles elimination status in November 2026. 3. Let's also check if there are other recent approvals or trial readouts, or space launches. Wait! The Nancy Grace Roman Space Telescope launch is scheduled for August 30, 2026. Let's verify if there is any update on that. Let's do a search on "Pasatru" AND "Regeneron" OR "gopinicline" OR "FOP" OR "activin A". Let's see what the generic name is and when it was approved.

Wow, this is an incredible development. Regeneron's garetosmab-grts was approved as **Pasatru** on August 19, 2026. Let's look at the details: - **Drug**: Pasatru (garetosmab-grts) - **Indication**: To reduce the formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). - **Mechanism**: Blocks Activin A, a protein discovered by Regeneron scientists to be critical in driving HO lesions (abnormal bone growth in muscles, tendons, ligaments, and connective tissues). - **Study**: Phase 3 OPTIMA trial (63 participants aged 18+). At 56 weeks, Pasatru 10 mg/kg demonstrated a 90% reduction in new HO lesions compared to placebo (2 lesions vs 19 lesions), and Pasatru 3 mg/kg demonstrated a 94% reduction (1 lesion vs 19 lesions). - **Secondary Endpoints**: Clinician-assessed flare-ups were reduced by 88% in the 10 mg/kg group (9 flare-ups vs 66 for placebo). Low-dose 3 mg/kg showed a 15% reduction (53 flare-ups). - **Administration**: Given intravenously once monthly (every 4 weeks). Weight-based starting dose is 10 mg/kg, but can be reduced to 3 mg/kg if not tolerated. Can be administered in home infusion settings. - **Safety**: Side effects include abscess, acne, increased hair growth, madarosis (loss of eyebrows), oral ulcers, epistaxis (nosebleeds), folliculitis, paronychia, and rash. - **Price**: Annual list price ranges from $693K to $2.1M based on weight. Wait, are there any other major updates? Let's check: 1. **The Nancy Grace Roman Space Telescope launch**: The launch is scheduled for August 30, 2026. Let's see if there are any recent updates about the schedule or preparations. 2. **H5N1 bird flu transmission to poultry or local wildlife in Australia or New Zealand**: Let's check these ongoing watches. 3. **U.S. measles outbreak and vaccination exemption drop-offs**: This is highly relevant to our watch on the U.S. measles elimination status. Let's do a search on measles outbreaks in Iowa, Pennsylvania, and other states. Let's search for "Nancy Grace Roman Space Telescope" launch status.

This is perfect. The launch of NASA's Nancy Grace Roman Space Telescope is confirmed and scheduled for **August 30, 2026, at 7:26 am EDT (11:26 UTC)** aboard a SpaceX Falcon Heavy rocket. It is nine months ahead of its original schedule. Wait, let's look at the remaining watches: 1. **H5N1 bird flu in Australia or New Zealand**: Let's do a quick search on H5N1 avian influenza in Australia or New Zealand to see if there are any recent detections or updates. 2. **U.S. measles outbreak / elimination status**: Let's search for "measles" AND "elimination status" OR "exemptions" OR "outbreak" AND "CDC" OR "PAHO" 2026 to see if there is any new trend. Let's check these.

This is a massive update on H5N1 in Australia and New Zealand. Let's look at the details: - **Tasmania detection**: Tasmania reported its first confirmed case of H5N1 avian influenza on August 13, 2026. This means the deadly strain has now been detected in every Australian state! - **Victoria / Little Penguins**: Australia has kicked off a vaccination program for Little Penguins in the state of Victoria after the first death from bird flu was reported in the breed (reported August 17, 2026). - **Wild birds in Australia**: Over the past week, a further 60 wild birds have tested positive for the H5N1 highly pathogenic avian influenza (HPAI) virus in Australia, bringing the total of confirmed wild birds to 102. - **New Zealand situation**: In New Zealand, two wild birds in the Wellington region have tested positive for H5N1, with no further detections since mid-July and no evidence of widespread mortality in wildlife or spread into poultry. This means the watch on New Zealand transmission to poultry or wildlife sanctuaries is still ongoing but active. Let's do a search on the US measles outbreak/elimination status. This is very important for our watch.

This is an incredibly rich set of news. Let's look at the details: - **Exemption spike**: On August 17, 2026, the CDC released the 2025-2026 kindergarten vaccination data. It showed that kindergarten vaccine exemptions have jumped to another record high, with **4.2%** of kindergarten students exempted from at least one vaccine, up from 3.6% in the previous year. - **Measles cases**: As of August 13, 2026, there are **2,566 confirmed measles cases** reported in the United States in 2026, which is a record-breaking 35-year high. - **Elimination status risk**: This puts the U.S. at severe risk of losing its official measles elimination status (held since 2000) when PAHO evaluates the data in November 2026. The CDC's new data shows a major drop-off in coverage, falling well below the 95% threshold required to maintain herd immunity. Let's check if there are any other open threads or prior notes we should update. Let's see: - `saol-therapeutics-sl1009-mitochondrial-disease-fda-acceptance` - this is for SL1009 (sodium dichloroacetate / DCA). The watch is for PDUFA of December 30, 2026. No update on that yet. - `capricor-deramiocel-regulatory-crisis-dmd` - this was about the CTGTAC meeting on July 29, 2026. Let's see if there is any update on Capricor or FDA decision since July. - `fda-crl-public-disclosure-policy` - our previous finding on Complete Response Letter transparency policy. Let's check if there are any updates on that. Wait! Let's search for Capricor's deramiocel FDA advisory committee or decision. Let's do a search on "Capricor" "deramiocel" OR "CAP-1002" to see if there is anything new.

This is highly relevant! Let's fetch `https://www.biopharmadive.com/news/capricor-fda-vote-deramiocel-duchenne-cardiomyopathy/826465/` or `https://www.fiercebiotech.com/biotech/fda-adcomm-shoots-down-capricors-duchenne-cell-therapy-after-meeting-marked-statistical` to get the exact voting results and the outcome of the July 29, 2026 CTGTAC advisory committee meeting for deramiocel. This is a crucial update to our prior finding `capricor-deramiocel-regulatory-crisis-dmd`. Let's fetch it.

This is an outstanding, detailed update. Let's summarize the key developments from this adcomm: - **Voting Result**: On July 29, 2026, the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted **9-3 against** the effectiveness of Capricor Therapeutics' deramiocel (CAP-1002) for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). - **Core Disagreement**: The FDA and Capricor fundamentally disagreed on whether the Phase 3 HOPE-3 trial was successful. Capricor claimed success based on its Statistical Analysis Plan (SAP) version 3.0, while the FDA maintained the trial failed based on SAP 1.1. - **LVEF and PUL 2.0 Endpoints**: Under Capricor's last-minute analysis change, the p-value for the secondary LVEF endpoint was still not statistically significant at 0.09 (and raised concerns about increased left ventricular volume). On the primary skeletal muscle endpoint (PUL 2.0), Capricor claimed a statistically significant p-value of 0.029 using a percent change model, but the FDA asserted that the pre-specified absolute change analysis was not statistically significant (p-value of 0.24). - **Upcoming PDUFA / Decision Date**: The FDA's final regulatory decision on the BLA is expected by **August 22, 2026** (which is in 3 days!). Wait, since today is August 19, 2026, the FDA decision on deramiocel is coming up on August 22, 2026. This is a perfect dated catalyst / watch that we can register or keep track of! Let's check if there is an existing watch for Capricor's final approval. No, we don't have an existing watch for Capricor's final approval, but we do have a prior note `capricor-deramiocel-regulatory-crisis-dmd`. We should absolutely update that note with these new details of the July 29, 2026 adcomm vote. Let's review our findings so far. Let's write down the key notes we want to update or create: 1. **Moderna & Merck's mRNA Cancer Vaccine (intismeran autogene / V940 / mRNA-4157)**: Landmark Phase 3 INTerpath-001 trial success in melanoma. This represents the first positive Phase 3 readout for an individualized neoantigen therapy (INT) and for an mRNA-based cancer therapy, demonstrating statistically significant and clinically meaningful improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) compared to Keytruda alone. This is a brand new finding. 2. **Ultragenyx's GENGLYCOS (pariglasgene brecaparvovec-opnr / DTX401)**: FDA granted accelerated approval on August 19, 2026, as the first-ever gene therapy for glycogen storage disease type Ia (GSDIa) in patients aged 8 and older. This is a brand new finding. 3. **Regeneron's Pasatru (garetosmab-grts)**: FDA granted approval on August 19, 2026, as the first and only treatment demonstrating a reduction in new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). This is a brand new finding. 4. **U.S. Measles Elimination Status Crisis**: Kindergarten vaccine exemptions have hit a record high of 4.2% (CDC data released August 17, 2026), while 2026 U.S. measles cases have reached a 35-year high of 2,566 cases as of August 13, 2026. This puts the U.S. at imminent risk of losing its measles elimination status when PAHO evaluates it in November 2026. This relates directly to our watch `PAHO decision on U.S. measles elimination status` (id: `01a0170e-5080-7e51-be48-73dbb4c8026d`). We should record a watch event or write a note! Wait, the watch triggers in November 2026, but this is a massive intermediate development. We should write a new note about it or update/create a note. Let's create a note on this. 5. **Capricor's Deramiocel Regulatory Crisis**: We can update the prior note `capricor-deramiocel-regulatory-crisis-dmd` with the details of the July 29, 2026 CTGTAC meeting where the panel voted 9-3 against its effectiveness. We can also register a watch for the upcoming FDA regulatory decision on deramiocel, expected by August 22, 2026. 6. **H5N1 Spread in Australia**: Tasmania has confirmed its first case, meaning H5N1 is now in every Australian state. Penguin vaccinations have begun in Victoria. This is a great update to our ongoing watch `Australia H5N1 transmission to poultry or local wildlife` (id: `019f2f50-7f4d-7361-8f05-cdf170c2d727`). We can record an ongoing event for this watch! Let's do this systematically. First, let's call `record_event` on the ongoing watch `Australia H5N1 transmission to poultry or local wildlife` (id: `019f2f50-7f4d-7361-8f05-cdf170c2d727`). Wait, the watch description is: "Monitor whether the newly arrived H5N1 avian influenza strain jumps from migratory seabirds to local Australian wildlife, marine mammals (e.g. fur seals), or commercial poultry farms." The recent news says: "Tasmania has confirmed its first H5N1 case, meaning the deadly strain has now been detected in every Australian state" and "Australia has kicked off a vaccination program for Little Penguins in the state of Victoria after the first death from bird flu was reported in the breed." This represents transmission to local Australian wildlife (Little Penguins) and further geographic spread. Let's call `record_event` on this.

Excellent. Now let's check the other watches. Are there any other watches that have fired? - `Launch of NASA's Nancy Grace Roman Space Telescope` (id: `019fb013-39c2-71d8-932b-66e49c963e6a`) is scheduled for August 30, 2026. Today is August 19, 2026, so it has not fired yet. - `CARDIO-TTRansform full dataset presentation at ESC Congress 2026` (id: `019f490e-b47d-7dea-817e-56ffbad19c83`) is scheduled for late August 2026 at the ESC Congress. Let's do a search on "CARDIO-TTRansform" OR "eplontersen" ESC 2026 to see if there is any early release or if it's still upcoming. Let's do that quickly.

Interesting! The ESC Congress is scheduled for August 28-31, 2026, and the CARDIO-TTRansform Hot Line Session 1 is scheduled for August 28, 2026. The full dataset has not been presented yet, but there is active discussion about the topline failure of eplontersen (Wainua) to meet its primary endpoint in CARDIO-TTRansform, which was announced a month ago. So this watch is still active and we will monitor it in late August. Let's write our findings now! Wait, let's write the findings one by one using the `write_note` tool. First: **Merck and Moderna's mRNA cancer vaccine (intismeran autogene, V940/mRNA-4157)**. Let's choose a stable slug: `moderna-merck-mrna-cancer-vaccine-melanoma-success` or `mrna-cancer-vaccine-melanoma-interpath`. Let's use `mrna-cancer-vaccine-melanoma-interpath`. Wait! Is there an existing slug for this? Let's check our prior findings: - `hhs-clinical-trials-reform-operation-trailblazer` - `fda-crl-public-disclosure-policy` - `saol-therapeutics-sl1009-mitochondrial-disease-fda-acceptance` - `capricor-deramiocel-regulatory-crisis-dmd` None of them are about the mRNA cancer vaccine. So we can mint a fresh slug: `mrna-cancer-vaccine-melanoma-interpath`. Let's write this note. We need to follow the body shape strictly: - No YAML frontmatter. - Title is the first `# ` heading. - Carry 1-2 representative verbatim quotes, kept with their links. - Interpret. - Sources block. Let's prepare the first note. Title: **Merck and Moderna's Personalized mRNA Cancer Vaccine Succeeds in Phase 3 Melanoma Trial** Verbatim quote from Merck's press release: > "At a pre-specified interim analysis, intismeran in combination with KEYTRUDA as adjuvant therapy demonstrated statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for patients with completely resected stage IIB, IIC, III or IV cutaneous melanoma who had not undergone prior treatment with systemic therapy." And quote from Prof. Georgina Long: > "Today’s results represent a landmark moment for adjuvant melanoma treatment. This is the first Phase 3 study to show that intismeran, a treatment designed based on the unique mutational ‘fingerprint' of a patient's own tumor, given in combination with pembrolizumab can reduce the risk of recurrence or death in patients with completely resected stage IIB-IV melanoma compared to KEYTRUDA alone..." Let's call `write_note` for the mRNA cancer vaccine.

Excellent. Now let's write the second note on **Ultragenyx's GENGLYCOS (pariglasgene brecaparvovec-opnr, DTX401)**. Let's choose a stable slug: `ultragenyx-genglycos-gene-therapy-gsdia-approval` or `genglycos-gsdia-gene-therapy-approval`. Let's use `genglycos-gsdia-gene-therapy-approval`. Verbatim quote from the press release: > "The U.S. FDA has granted accelerated approval for GENGLYCOS (pariglasgene brecaparvovec-opnr), also known as DTX401, for adult and pediatric patients ≥8 years with glycogen storage disease type Ia (GSDIa). GENGLYCOS is the first FDA‑approved treatment designed to address the underlying cause of GSDIa and Ultragenyx’s first approved gene therapy..." Let's call `write_note` for GENGLYCOS.

Now let's write the third note on **Regeneron's Pasatru (garetosmab-grts)**. Let's choose a stable slug: `regeneron-pasatru-fop-approval` or `pasatru-fop-garetosmab-approval`. Let's use `pasatru-fop-garetosmab-approval`. Verbatim quote from the press release: > "The U.S. Food and Drug Administration (FDA) has granted approval for Pasatru™ (garetosmab-grts) to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP)." And quote from George D. Yancopoulos: > "The approval of Pasatru is the culmination of decades of pioneering research that Regeneron has pursued alongside the FOP community, rooted in our discovery of the role that Activin A plays in driving this disease..." Let's call `write_note` for Pasatru.

Now let's write the fourth note on the **U.S. Measles Elimination Status Crisis**. Let's choose a stable slug: `us-measles-outbreaks-elimination-crisis-2026` or `us-measles-elimination-status-crisis`. Let's use `us-measles-elimination-status-crisis`. Verbatim quote from the CDC: > "As of August 13, 2026, 2,566 confirmed* measles cases were reported in the United States in 2026." Verbatim quote from CIDRAP: > "More kindergarten students (4.2%) were exempted from at least one vaccination during the 2025-26 school year than in the previous year (3.6%), the Centers for Disease Control and Prevention reported today." Let's call `write_note` for the measles elimination status crisis.

Excellent. Now let's update the prior finding on Capricor: `capricor-deramiocel-regulatory-crisis-dmd`. Let's review what was previously written about Capricor (from semantic search preview in the kickoff message): "Capricor's Deramiocel Faces Regulatory Integrity Crisis as FDA Staff Disagrees with Phase 3 Success Claims (slug: capricor-deramiocel-regulatory-crisis-dmd, score 0.37): On July 27, 2026, the U.S. Food and Drug Administration (FDA) released highly critical briefing documents ahead of the July 29 Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meeting..." We will update `capricor-deramiocel-regulatory-crisis-dmd` to include the July 29, 2026 CTGTAC meeting outcome (voted 9-3 against) and the core statistical disputes. Let's call `write_note` on `capricor-deramiocel-regulatory-crisis-dmd` with this update. Since we are updating, we reuse the slug `capricor-deramiocel-regulatory-crisis-dmd`. Let's write the updated body.

Awesome. Now let's register any forward-looking watches or resolve any threads. Wait, let's look at the threads first: 1. Is there an existing thread for Capricor deramiocel? Let's check `list_threads`. Wait, there are no open threads of kind `question` or `investigation` for Capricor, but there is a watch: Ah, wait! Is there a watch for Capricor? Let's check the listed threads: The threads list doesn't show a watch for Capricor. So we can record a new watch for Capricor's final FDA decision! The target action date is August 22, 2026. Let's call `record_watch` for the final FDA regulatory decision on Capricor's deramiocel. Wait, let's verify if there is any other watch we should record. What about the Nancy Grace Roman Space Telescope? We have an existing watch: - `Launch of NASA's Nancy Grace Roman Space Telescope` (id: `019fb013-39c2-71d8-932b-66e49c963e6a`), scheduled for August 30, 2026. This is already registered. What about the Merck/Moderna mRNA cancer vaccine? We should record a watch for the regulatory filing/submission of the mRNA cancer vaccine (intismeran autogene) to the FDA, which is expected following this Phase 3 success. Let's record a watch for the FDA regulatory submission of intismeran autogene in adjuvant melanoma. Let's record a watch for the FDA decision on Capricor's deramiocel. Let's call `record_watch` for Capricor's deramiocel FDA decision. Target date: August 22, 2026. Since it's a specific date, it is a `dated_catalyst` and `cardinality` is `one_shot`. Let's do that.

Excellent. Now let's record a watch for the regulatory submission of the Merck/Moderna mRNA cancer vaccine (intismeran autogene) to the FDA. Let's make it a `one_shot` watch under `dated_catalyst` or `tripwire` or `thesis_breaker`. Let's use `dated_catalyst` or `tripwire`. Let's use `tripwire` or `dated_catalyst` with a target date of Q4 2026/early 2027. Let's set the fire_date to December 31, 2026. Let's do that.

Perfect! Now, let's review if we have addressed any existing threads. Let's check the threads listed in `list_threads`: - `PAHO decision on U.S. measles elimination status` (id: `01a0170e-5080-7e51-be48-73dbb4c8026d`) - This is a watch that triggers in November 2026. We wrote a note about the intermediate crisis, but the final decision is not yet made, so the watch remains open. - `Launch of NASA's Nancy Grace Roman Space Telescope` (id: `019fb013-39c2-71d8-932b-66e49c963e6a`) - This is scheduled for August 30, 2026. It remains open. - `Australia H5N1 transmission to poultry or local wildlife` (id: `019f2f50-7f4d-7361-8f05-cdf170c2d727`) - This is an ongoing watch. We recorded an event on it, and it remains open. Let's double check if there are any other notes we should write or update. Wait, let's look at the prior notes list: - `fda-crl-public-disclosure-policy` (score 0.43) - `hhs-clinical-trials-reform-operation-trailblazer` (score 0.44) - `saol-therapeutics-sl1009-mitochondrial-disease-fda-acceptance` (score 0.39) - `capricor-deramiocel-regulatory-crisis-dmd` (score 0.37) - We just updated this note successfully! Let's review if there are any other new major developments this week. We had: - **Merck/Moderna mRNA cancer vaccine Phase 3 success** (created `mrna-cancer-vaccine-melanoma-interpath`) - **Ultragenyx's GENGLYCOS accelerated FDA approval** (created `genglycos-gsdia-gene-therapy-approval`) - **Regeneron's Pasatru FDA approval** (created `pasatru-fop-garetosmab-approval`) - **U.S. measles crisis and vaccine exemptions spike** (created `us-measles-elimination-status-crisis`) - **Capricor's deramiocel adcomm outcome** (updated `capricor-deramiocel-regulatory-crisis-dmd`) - **Australia H5N1 spread and penguin vaccination** (recorded watch event) This is a highly successful and substantive research cycle with rich primary findings, verbatim quotes, stable slugs, and clear forward-looking watches. I will call `finish_cycle` now.

I have successfully completed this research cycle for the health and science tracking topic. Here is a summary of the key findings and updates recorded in this cycle: ### 1. New Findings Established * **Merck and Moderna’s Personalized mRNA Cancer Vaccine Succeeds in Phase 3 (`[[mrna-cancer-vaccine-melanoma-interpath]]`)**: * **What happened**: In a historic milestone for oncology, the Phase 3 **INTerpath-001** trial of **intismeran autogene** (V940/mRNA-4157) in combination with Keytruda met its primary endpoint of recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with completely resected Stage IIB-IV melanoma. This represents the first positive Phase 3 readout for both an individualized neoantigen therapy (INT) and an mRNA-based cancer therapy. * **Quote**: *"Today’s results represent a landmark moment for adjuvant melanoma treatment. This is the first Phase 3 study to show that intismeran, a treatment designed based on the unique mutational ‘fingerprint' of a patient's own tumor, given in combination with pembrolizumab can reduce the risk of recurrence or death..."* — Professor Georgina Long, Study Principal Investigator. * **FDA Grants Accelerated Approval to Ultragenyx's GENGLYCOS (`[[genglycos-gsdia-gene-therapy-approval]]`)**: * **What happened**: The FDA granted accelerated approval on August 19, 2026, to **GENGLYCOS (pariglasgene brecaparvovec-opnr / DTX401)** for patients aged 8 and older with Glycogen Storage Disease Type Ia (GSDIa). It is the first gene therapy approved for GSDIa, significantly reducing patients' daily oral cornstarch requirements (p<0.001 in the Phase 3 GlucoGene study). * **Quote**: *"GENGLYCOS is the first FDA‑approved treatment designed to address the underlying cause of GSDIa and Ultragenyx’s first approved gene therapy, and it reduces daily cornstarch intake as an adjunct to nutritional management."* * **FDA Approves Regeneron's Pasatru for Fibrodysplasia Ossificans Progressiva (`[[pasatru-fop-garetosmab-approval]]`)**: * **What happened**: The FDA approved Regeneron's **Pasatru (garetosmab-grts)** on August 19, 2026, to reduce new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with FOP (an ultra-rare genetic disease that turns muscles and tissues into bone). In the Phase 3 OPTIMA trial, Pasatru demonstrated a 90% reduction in new HO lesions and an 88% reduction in clinician-assessed flare-ups. * **Quote**: *"At 56 weeks, both doses of Pasatru, 10 mg/kg (n=23) and 3 mg/kg (n=19), met the primary endpoint and were highly efficacious in reducing the total number of new HO lesions as compared to placebo (n=21), demonstrating a 90% ... and 94% ... reduction, respectively..."* * **U.S. Measles Elimination Status in Jeopardy (`[[us-measles-elimination-status-crisis]]`)**: * **What happened**: Active measles cases in the U.S. have reached a 35-year high of **2,566 cases** as of August 13, 2026. Concurrently, CDC data released on August 17, 2026, revealed that kindergarten vaccine exemptions have spiked to a record high of **4.2%**, pushing vaccination coverage dangerously below the 95% herd immunity threshold. This places the U.S. at severe risk of losing its official measles elimination status when PAHO evaluates the data in November 2026. * **Quote**: *"More kindergarten students (4.2%) were exempted from at least one vaccination during the 2025-26 school year than in the previous year (3.6%), the Centers for Disease Control and Prevention reported today."* --- ### 2. Prior Findings Refined and Updated * **Capricor's Deramiocel Regulatory Crisis (`[[capricor-deramiocel-regulatory-crisis-dmd]]`)**: * **What happened**: Updated the prior note to detail the outcome of the July 29, 2026 FDA Advisory Committee (CTGTAC) meeting. The panel voted **9-3 against** the effectiveness of deramiocel in DMD-associated cardiomyopathy. The meeting was marked by a contentious dispute between the FDA and Capricor over statistical analysis plans, with the FDA pointing out that the pre-specified absolute change analysis for PUL 2.0 was not statistically significant (p=0.24) and raising concerns over increased left ventricular volume. --- ### 3. Tracked Catalysts and Registered Watch Events * **H5N1 Spread in Australia (`019f2f50-7f4d-7361-8f05-cdf170c2d727`)**: Recorded a watch event noting that Tasmania has confirmed its first H5N1 case (meaning the strain is now in every Australian state) and that a penguin vaccination campaign has begun in Victoria following the first death of a Little Penguin. * **Capricor's Final FDA Decision Watch (`01a01c33-9e31-7d9f-8903-d5f70ed4e9a0`)**: Registered a new one-shot watch for the FDA's final regulatory decision on the BLA for deramiocel, expected on or before **August 22, 2026**. * **Merck and Moderna BLA Submission Watch (`01a01c33-a9b2-7ac7-b286-c7d9b8d78905`)**: Registered a new one-shot watch to monitor the formal regulatory BLA submission of intismeran autogene in resected melanoma, targeted for late 2026.